The evolving role of targeted radioligand therapy in small cell and non-small cell lung cancer: a systematic review

Abstract

Background: Targeted radioligand therapy (TRT) is an emerging theranostic modality in oncology. While well established in neuroendocrine and prostate cancers, its role in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) remains investigational. This systematic review summarizes current evidence evaluating TRT in lung cancer.

Methods: A Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of PubMed, Embase, and Scopus (2000–November 2025) was conducted. Original studies evaluating TRT in SCLC or NSCLC were included. Primary outcomes were tumor response, disease-control rate, and treatment-related toxicity. Secondary outcomes included progression-free survival, overall survival, and dosimetry. Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I) tool.

Results: From 2,453 records, 15 studies were included, reporting 358 lung cancer patients, of whom 105 received TRT. Disease-control rates reached up to 78% in mixed NSCLC/SCLC cohorts. In SCLC, somatostatin receptor-targeted peptide receptor radionuclide therapy demonstrated heterogeneous disease control (0–50%), with [¹⁷⁷Lu]Lu-labeled agents showing more favorable outcomes than [⁹⁰Y]Y-based therapy. The most favorable outcomes were a median progression-free survival of 11.9 months and an overall survival of 16 months in responders. In NSCLC, fibroblast activation protein (FAP)-targeted agents such as [¹⁷⁷Lu]Lu-FAP-2286 demonstrated partial metabolic responses, including a 44.4% response rate and 78% disease control in a mixed cohort. Severe toxicities were infrequent.

Discussion: TRT is a promising but experimental option for advanced lung cancer. Early efficacy signals exist for strong somatostatin receptor (SSTR)-targeted therapy in SCLC and FAP-targeted therapy in NSCLC, but evidence remains limited. Prospective trials with standardized protocols and dosimetry are needed to define TRT’s role in lung cancer treatment.

Keywords

SCLC / NSCLC / targeted radionuclide therapy / theranostics / PRRT

References

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[2] Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017; 7: 193.

[3] Blackhall F, Girard N, Livartowski A, McDonald L, Roset M, Lara N, et al. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. 2023; 13: e052556.

[4] Liang B, Tong C, Nong J, Zhang Y. Histological Subtype Classification of Non-Small Cell Lung Cancer with Radiomics and 3D Convolutional Neural Networks. J Imaging Inform Med. 2024; 37: 2895-909.

[5] Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of NonSmall-Cell Lung Cancer. Lung. 2025; 203: 53.

[6] Niho S. Treatment of small cell lung cancer; advances and future prospects. Respir Investig. 2025; 63: 680-5.

[7] Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics Global Market and Future Developments. Semin Nucl Med. 2024; 54: 622-33.

[8] Al-Ibraheem A, Brink A, Lee ST, De Los Reyes A, Paez D, Craviolatti PS, et al. Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. Semin Nucl Med. 2025; 55: 1032-44.

[9] Watabe T, Hirata K, Iima M, Yanagawa M, Saida T, Sakata A, et al. Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med. 2025; 39: 909-21.

[10] Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025; 66: 757-63.

[11] Abdlkadir AS, Al-Adhami D, Al-Rasheed U, Jreige M, Mahafza W, Al-Khawaldeh K, et al. PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review. Q J Nucl Med Mol Imaging. 2025; 69: 99-117.

[12] Al-Ibraheem A, Abdlkadir AS, Sweedat DA, Maus S, Al-Rasheed U, Salah S, et al. From Despair to Hope: First Arabic Experience of¹⁷⁷Lu-PSMA and¹⁶¹Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2024; 16: 1974.

[13] Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer. 2019; 20: e376-92.

[14] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.

[15] Calderon Martinez E, Ghattas Hasbun PE, Salolin Vargas VP, García-González OY, Fermin Madera MD, Rueda Capistrán DE, et al. A comprehensive guide to conduct a systematic review and meta-analysis in medical research. Medicine (Baltimore). 2025; 104: e41868.

[16] Selçuk AA. A Guide for Systematic Reviews: PRISMA. Turk Arch Otorhinolaryngol. 2019; 57: 57-8.

[17] Saad Ruzzeh, Serin Moghrabi. The Evolving Role of Targeted Radioligand Therapy in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review. PROSPERO 2025 CRD420251238530 [Internet]. NIHR; c2025 [cited 2025 Nov 25]. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251238530

[18] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016; 5: 210.

[19] Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016; 62: 132-7.

[20] O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016; 280: 576-84.

[21] Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021; 112: 90-2. Spanish.

[22] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355: i4919.

[23] Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer. Clin Nucl Med. 2024; 49: 830-7.

[24] Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study. Clin Nucl Med. 2021; 46: e523-30.

[25] Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer. 2004; 45: 365-71.

[26] Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, et al. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol. 2013; 8: 1095-101.

[27] Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006; 21: 5-14.

[28] Liu H, Guo R, Zhang X, Ji H, Sun S, Sun S, et al. Safety and efficacy of¹⁷⁷Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study. Eur J Nucl Med Mol Imaging. 2026; 53: 1869-80.

[29] Fu H, Huang J, Zhao L, Chen Y, Xu W, Cai J, et al. 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study. Clin Cancer Res. 2025; 31: 1415-26.

[30] Serfling SE, Hartrampf PE, Zhi Y, Higuchi T, Kosmala A, Serfling J, et al. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer. Clin Nucl Med. 2023; 48: 309-14.

[31] Lapa C, Hänscheid H, Wild V, Pelzer T, Schirbel A, Werner RA, et al. Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget. 2016; 7: 20033-40.

[32] Şen F, Sheikh GT, von Hinten J, Schindele A, Kircher M, Dierks A, et al. In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target. Cancers (Basel). 2023; 15: 3595.

[33] Aggarwal P, Anwariya A, Kaur K, Satapathy S, Sood A, Singh N, et al. PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss? Clin Nucl Med. 2026; 51: e120-2.

[34] Rao Z, Zhang Y, Liu L, Wang M, Zhang C. [¹⁷⁷Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases. Eur J Nucl Med Mol Imaging. 2023; 50: 1266-7.

[35] Yang H, Liu H, Zhang Y, Zhang Y, Chen Y. Metastatic Lung Adenocarcinoma Received Combined 177Lu-FAP-2286 Radiation Therapy and Targeted Therapy. Clin Nucl Med. 2024; 49: 569-71.

[36] Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S. Significant response to [²²⁵Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025; 52: 2743-4.

[37] van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006; 47: 1599-606.

[38] Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, et al. Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. Nucl Med Mol Imaging. 2025; 59: 50-61.

[39] Verwer EE, Zegers CML, van Elmpt W, Wierts R, Windhorst AD, Mottaghy FM, et al. Pharmacokinetic modeling of a novel hypoxia PET tracer [¹⁸F]HX4 in patients with non-small cell lung cancer. EJNMMI Phys. 2016; 3: 30.

[40] Urso L, Napolitano R, Speltri G, Tuncel M, Badrane I, Uccelli L, et al. ⁶⁸Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives. Cancers (Basel). 2025; 17: 1504.

[41] Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, et al. Safety of [¹⁷⁷Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022; 49: 4440-51.